Avenzo Therapeutics, Inc.
🇺🇸United States
Clinical Trials
4
Active:0
Completed:0
Trial Phases
2 Phases
Phase 1:2
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (50.0%)Not Applicable
1 (25.0%)phase_1_2
1 (25.0%)Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Not Applicable
Recruiting
- Conditions
- Solid Tumor CancerLocally AdvancedMetastatic Solid TumorsUrothelial Cancer
- Interventions
- Drug: AVZO-103Drug: Combination Agent
- First Posted Date
- 2025-09-26
- Last Posted Date
- 2025-11-12
- Lead Sponsor
- Avenzo Therapeutics, Inc.
- Target Recruit Count
- 355
- Registration Number
- NCT07193511
- Locations
- 🇺🇸
Avenzo Therapeutics Recruiting Site, Austin, Texas, United States
Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Phase 1
Recruiting
- Conditions
- Solid Tumor CancerLocally AdvancedMetastatic Solid TumorsLung CancersEpithelial Tumor
- Interventions
- First Posted Date
- 2025-06-26
- Last Posted Date
- 2025-09-19
- Lead Sponsor
- Avenzo Therapeutics, Inc.
- Target Recruit Count
- 430
- Registration Number
- NCT07038343
- Locations
- 🇺🇸
Avenzo Therapeutics Recruiting Site, Fairfax, Virginia, United States
Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced Solid TumorHR+/HER2- Breast CancerHR+, HER2-, Advanced Breast CancerCDK Gene MutationCCND1 Gene AmplificationCDK4 Gene Amplification
- Interventions
- First Posted Date
- 2025-05-31
- Last Posted Date
- 2025-09-15
- Lead Sponsor
- Avenzo Therapeutics, Inc.
- Target Recruit Count
- 380
- Registration Number
- NCT06998407
- Locations
- 🇺🇸
Avenzo Therapeutics Recruiting Site, Fairfax, Virginia, United States
A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti_Tumor Activity of AVZO-021 as a Single Agent and in Combination Therapy in Patients with Advanced Solid Tumors.
Phase 1/2
Recruiting
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2023-05-19
- Last Posted Date
- 2025-11-19
- Lead Sponsor
- Avenzo Therapeutics Inc.
- Target Recruit Count
- 52
- Registration Number
- 2024-517339-30-00
- Locations
- 🇺🇸
Perlmutter Cancer Center at NYU Langone Hospital - Long Island, Mineola, New York, United States
🇺🇸NYU Langone Medical Center (Tisch Hospital), New York, New York, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
News
No news found